1Seidman AD, O'Shaughnessy J, Misaet J. Single-agent Capecitabine: a reference treatment for Taxane-pretreated metastatic breast cancer[J]. Oncolagist, 2002, 7(auppl 6) :20 -28.
2Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer[J]. Oncologist, 2001,6( 1 ) :56 -64.
3Schueller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal patients[ J]. Cancer Chemother Pharmacol, 45:291 - 297,2000.
4Blum JL, dieras V, Lo Russo PM, et al. Multicenter, phase Ⅱ study of capecitabine in taxane-pretreated metastatic breast carcinoma patients[ J]. Cancer, 2001,92 : 1759 - 1768.
5Fumoleau P, Laigillier R, Trillet-Lenoir V, et al. Phase Ⅱ study of capecitabine ( Xeloda ) in pts with advanced breast cancer ( ABC ), previously treated with anthracyclines and taxanes[ J]. Breast Cancer Res Treat,2001, 69:285a.
6Reichardt P, Von Minckwitz G, Luck HJ, et al. Capecitabine:the new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large muhicenter phase Ⅱ trial[J]. Eur J Cancer, 2001, 37 ( suppl6) :S191a.
7Ishikawa T, Fukase Y, Yamamoto T, et al. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine (capecitabine)[ J]. Biol Pharm Bull, 1998, 21 :713-717.
8Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of S-Fum by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts [ J ]. Biochem Pharmacol,1998, 55 : 1091 - 1097.
9Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts [ J ]. Cancer Res,1998, 58:685 -690.
10Venturini M. Rational development of capecitabine [ J ]. Eur J Cancer, 2002, 38:S3-S9.
